Please login to the form below

regorafenib

This page shows the latest regorafenib news and features for those working in and with pharma, biotech and healthcare.

NICE backs Pfizer’s Xeljanz for RA

Meanwhile, NICE has decided to remove Bayer ’s gastrointestinal stomach tumour (GIST) treatment Stivarga (regorafenib) from the cancer drugs fund (CDF) to make it routinely available to some patients on the

Latest news

Bayer's Nexavar backed by NICE for liver cancer

Amanda Cunnington, head of patient access at Bayer UK, said the company recently submitted its new HCC drug Stivarga (regorafenib) for review by NICE and the Scottish Medicines Consortium (SMC) "with
EMA clears Bayer's Stivarga for liver cancer

The European Medicines Agency (EMA) approved oral multikinase inhibitor Stivarga (regorafenib) for patients with HCC who have been treated first-line with Bayer's older drug Nexavar (sorafenib), matching the
FDA OK for Stivarga ends decade-long drought in liver cancer

Oral multikinase inhibitor Stivarga (regorafenib) has been cleared by the US regulator for patients with hepatocellular carcinoma (HCC) who have been previously treated with Bayer's older drug Nexavar (sorafenib).
Bayer nets speedy US review for regorafenib in liver cancer

Bayer nets speedy US review for regorafenib in liver cancer. Priority review in HCC boosts hopes for rejuvenation of Stivarga to combat declining sales. ... Regorafenib - sold as Stivarga for colorectal and gastrointestinal stromal (GIST) tumours - has
Xarelto leads the charge at Bayer

Colorectal cancer and gastrointestinal stromal rumour (GIST) therapy Stivarga (regorafenib) disappointed however, with sales down 25% thanks to increased competition in the US, although Bayer is hoping to reinvigorate the product ... Initial results from

More from news
Approximately 8 fully matching, plus 35 partially matching documents found.

Latest Intelligence

Pharma deals during August 2013

To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Bayer’s former oncology head Robert Rosen joins AP Pharma

Rosen also led premarket activities for Stivarga (regorafenib) in its indications for gastrointestinal stromal tumours and colon cancer, as well as for alpharadin in prostate cancer.
Former Bayer oncology head Robert Rosen joins AP Pharma's board

He was also involved in pre-market activities for regorafenib in the treatment of patients with gastrointestinal stromal tumours and colon cancer, as well as alpharadin for prostate cancer.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Editor – Medical Education Agency – Bucks: Salary TBC

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Medical Writer - (London, Brighton or Copenhagen): Competitive

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Project Manager, Medical Communications, London: Excellent Salary

Senior Programme Executive: Salary TBC

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Senior Account Manager – Med Comms – Kent: Salary TBC

Senior Medical Writer: Great salary and benefits

Medical Writer, e-learning/ training, London: Excellent Salary

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Project Manager, Medical Communications, Oxford: Excellent Salary

Senior Account Manager or AD - Medical Communications: Salary TBC

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Editorial Director – Medical Education – Oxford: Negotiable

Senior Account Manager / Account Director: Great salary and bebefits

Scientific Director: Great salary and bebefits

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Senior Medical Writer: Great salary and bebefits

Subscribe to our email news alerts

PMHub

Add my company

Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...